FEATURED COMPANIES
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
- Wave Life Sciences Ltd.
1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: About this market
The Duchenne muscular dystrophy (DMD) therapeutics market analysis considers sales from both biologics and small molecules in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy to stop the progression of the disease will play a significant role in the biologics segment to maintain its market position. Also, our global DMD therapeutics market report looks at factors such as high unmet need, increasing strategic alliance, and patient assistance programs. However, high treatment costs, stringent regulatory environment, and adverse side effects of DMD therapeutics may hamper the growth of the DMD therapeutics industry over the forecast period.
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overview
High unmet need.
Duchenne muscular dystrophy led to the identification of the dystrophin gene, which is responsible for coding patients that helps in maintaining muscle cell membrane stability. This led to the identification of various therapeutic targets, such as dystrophin-based therapies like EXONDYS 51 and TRANSLARNA. However, the high costs of these drugs are restricting their penetration in many underdeveloped and developing countries. This has resulted in high unmet demand for affordable therapies that can reverse the progression of DMD. This is encouraging many leading vendors to introduce affordable novel therapies for the treatment. The strong distribution network of vendors coupled with the presence of reimbursement policies will lead to the expansion of the global Duchenne muscular dystrophy (DMD) therapeutics market at a CAGR of over 37% during the forecast period.
Increasing research funding
Advances in diagnostic methods is leading researchers and organizations to conduct research onresearch developing therapeutics for treating DMD. For instance, Muscular Dystrophy Association developed an innovative way to fund the research on moving new drug targets into clinical stages at a fast pace. On the other hand, organizations such as Duchenne UK provides research grants to vendors and researchers developing therapeutics for DMD. This increasing research funding is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few major players, the global Duchenne muscular dystrophy (DMD) therapeutics market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading Duchenne muscular dystrophy (DMD) therapeutics manufacturers, that include F. Hoffmann-La Roche Ltd., PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., Wave Life Sciences Ltd.
Also, the Duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The Duchenne muscular dystrophy (DMD) therapeutics market analysis considers sales from both biologics and small molecules in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy to stop the progression of the disease will play a significant role in the biologics segment to maintain its market position. Also, our global DMD therapeutics market report looks at factors such as high unmet need, increasing strategic alliance, and patient assistance programs. However, high treatment costs, stringent regulatory environment, and adverse side effects of DMD therapeutics may hamper the growth of the DMD therapeutics industry over the forecast period.
Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overview
High unmet need.
Duchenne muscular dystrophy led to the identification of the dystrophin gene, which is responsible for coding patients that helps in maintaining muscle cell membrane stability. This led to the identification of various therapeutic targets, such as dystrophin-based therapies like EXONDYS 51 and TRANSLARNA. However, the high costs of these drugs are restricting their penetration in many underdeveloped and developing countries. This has resulted in high unmet demand for affordable therapies that can reverse the progression of DMD. This is encouraging many leading vendors to introduce affordable novel therapies for the treatment. The strong distribution network of vendors coupled with the presence of reimbursement policies will lead to the expansion of the global Duchenne muscular dystrophy (DMD) therapeutics market at a CAGR of over 37% during the forecast period.
Increasing research funding
Advances in diagnostic methods is leading researchers and organizations to conduct research onresearch developing therapeutics for treating DMD. For instance, Muscular Dystrophy Association developed an innovative way to fund the research on moving new drug targets into clinical stages at a fast pace. On the other hand, organizations such as Duchenne UK provides research grants to vendors and researchers developing therapeutics for DMD. This increasing research funding is expected to have a positive impact on the overall market growth.
Competitive Landscape
With the presence of a few major players, the global Duchenne muscular dystrophy (DMD) therapeutics market is highly concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading Duchenne muscular dystrophy (DMD) therapeutics manufacturers, that include F. Hoffmann-La Roche Ltd., PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., Wave Life Sciences Ltd.
Also, the Duchenne muscular dystrophy (DMD) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
- Wave Life Sciences Ltd.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 07: MARKET SEGMENTATION BY TYPE
PART 09: GEOGRAPHIC LANDSCAPE
PART 11: DRIVERS AND CHALLENGES
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Global DMD therapeutics market pipeline: Overview
Exhibit 19: Global DMD therapeutics market pipeline: Snapshot
Exhibit 20: Type - Market share 2018-2023 (%)
Exhibit 21: Comparison by type
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 57: PTC Therapeutics Inc. - Vendor overview
Exhibit 58: PTC Therapeutics Inc. - Business segments
Exhibit 59: PTC Therapeutics Inc. - Organizational developments
Exhibit 60: PTC Therapeutics Inc. - Key offerings
Exhibit 61: PTC Therapeutics Inc. - Key customers
Exhibit 62: Santhera Pharmaceuticals - Vendor overview
Exhibit 63: Santhera Pharmaceuticals - Business segments
Exhibit 64: Santhera Pharmaceuticals - Organizational developments
Exhibit 65: Santhera Pharmaceuticals - Geographic focus
Exhibit 66: Santhera Pharmaceuticals - Key offerings
Exhibit 67: Santhera Pharmaceuticals - Key customers
Exhibit 68: Sarepta Therapeutics Inc. - Vendor overview
Exhibit 69: Sarepta Therapeutics Inc. - Business segments
Exhibit 70: Sarepta Therapeutics Inc. - Organizational developments
Exhibit 71: Sarepta Therapeutics Inc. - Geographic focus
Exhibit 72: Sarepta Therapeutics Inc. - Key offerings
Exhibit 73: Sarepta Therapeutics Inc. - Key customers
Exhibit 74: Wave Life Sciences Ltd. - Vendor overview
Exhibit 75: Wave Life Sciences Ltd. - Business segments
Exhibit 76: Wave Life Sciences Ltd. - Organizational developments
Exhibit 77: Wave Life Sciences Ltd. - Key offerings
Exhibit 78: Wave Life Sciences Ltd. - Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Definition of market positioning of vendors
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- The threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Biologics - Market size and forecast 2018-2023
- Small molecules - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-202
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
- Strong pipeline
- Increasing research funding
- Special drug designations
- Overview
- Landscape disruption
- Competitive scenario
- Vendors covered
- Vendor classification
- Market positioning of vendors
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
- Wave Life Sciences Ltd.
- Research methodology
- List of abbreviations
- Definition of market positioning of vendors
Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Global DMD therapeutics market pipeline: Overview
Exhibit 19: Global DMD therapeutics market pipeline: Snapshot
Exhibit 20: Type - Market share 2018-2023 (%)
Exhibit 21: Comparison by type
Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
Exhibit 24: Small molecules - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Small molecules - Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by type
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Europe
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Asia
Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in ROW
Exhibit 42: Key leading countries
Exhibit 43: Market opportunity
Exhibit 44: Impact of drivers and challenges
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 51: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 52: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 53: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 54: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 55: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 56: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 57: PTC Therapeutics Inc. - Vendor overview
Exhibit 58: PTC Therapeutics Inc. - Business segments
Exhibit 59: PTC Therapeutics Inc. - Organizational developments
Exhibit 60: PTC Therapeutics Inc. - Key offerings
Exhibit 61: PTC Therapeutics Inc. - Key customers
Exhibit 62: Santhera Pharmaceuticals - Vendor overview
Exhibit 63: Santhera Pharmaceuticals - Business segments
Exhibit 64: Santhera Pharmaceuticals - Organizational developments
Exhibit 65: Santhera Pharmaceuticals - Geographic focus
Exhibit 66: Santhera Pharmaceuticals - Key offerings
Exhibit 67: Santhera Pharmaceuticals - Key customers
Exhibit 68: Sarepta Therapeutics Inc. - Vendor overview
Exhibit 69: Sarepta Therapeutics Inc. - Business segments
Exhibit 70: Sarepta Therapeutics Inc. - Organizational developments
Exhibit 71: Sarepta Therapeutics Inc. - Geographic focus
Exhibit 72: Sarepta Therapeutics Inc. - Key offerings
Exhibit 73: Sarepta Therapeutics Inc. - Key customers
Exhibit 74: Wave Life Sciences Ltd. - Vendor overview
Exhibit 75: Wave Life Sciences Ltd. - Business segments
Exhibit 76: Wave Life Sciences Ltd. - Organizational developments
Exhibit 77: Wave Life Sciences Ltd. - Key offerings
Exhibit 78: Wave Life Sciences Ltd. - Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
FEATURED COMPANIES
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
- Wave Life Sciences Ltd.
The following companies are recognised as the key players in the global Duchenne muscular dystrophy (DMD) therapeutics market: F. Hoffmann-La Roche Ltd., PTC Therapeutics Inc., Santhera Pharmaceuticals, Sarepta Therapeutics Inc., Wave Life Sciences Ltd.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research funding.”
According to the report, one of the major drivers for this market is the high unmet need.
Further, the report states that one of the major factors hindering the growth of this market is high treatment costs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the increasing research funding.”
According to the report, one of the major drivers for this market is the high unmet need.
Further, the report states that one of the major factors hindering the growth of this market is high treatment costs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
- F. Hoffmann-La Roche Ltd.
- PTC Therapeutics Inc.
- Santhera Pharmaceuticals
- Sarepta Therapeutics Inc.
- Wave Life Sciences Ltd.
Note: Product cover images may vary from those shown
LOADING...
